Mirum Pharmaceuticals, Inc. (MIRM) has a consensus analyst rating of Buy, based on 18 analysts covering the stock. Of those, 18 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for MIRM is $116.70, representing a +20.4% upside from the current price of $96.9. Price targets range from a low of $95.00 to a high of $140.00.
